2,6-Dibutyl-4-sulfanylphenol | 94883-26-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯硫酚类
• 英文名称: 2,6-Dibutyl-4-sulfanylphenol
• CAS: 94883-26-8
• 化学式: C₁₄H₂₂OS
• 分子量: 238.39
• InChiKey: PIZADTKTMWJBAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  21.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISORDERS
  申请人：Stocker Roland O.

  公开号：US20100004333A1

  公开（公告）日：2010-01-07

  The present invention relates to compounds and methods for the treatment of cardiovascular diseases and disorders. Compounds according to the present invention may comprise an optionally substituted phenyl ring linked to an aromatic or alkyl group by a spacer, wherein the spacer comprises two groups selected from selenium, sulfur, S(O) and S(O) 2 and may further optionally comprise an alkylene, alkenylene, cycloalkylene or arylene moiety between the respective selenium, sulfur, S(O) and S(O) 2 groups.

  本发明涉及化合物和方法，用于治疗心血管疾病和紊乱。根据本发明的化合物可能包括一个可选取代的苯环，通过一个间隔连接到一个芳香族或烷基团，其中该间隔包括从硒，硫，S（O）和S（O）2中选择的两个基团，并且还可以在各自的硒，硫，S（O）和S（O）2基团之间进一步选择包括一个烷基，烯基，环烷基或芳基的基团。
• Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, AAA and stroke
  申请人：Cordis Corporation

  公开号：EP1974758A2

  公开（公告）日：2008-10-01

  Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organismfi reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic agents or compounds may also further reduce a biological organismis, reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or compounds may also be utilized to treat specific disorders, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

  医疗器械，尤其是植入式医疗器械，可以进行涂层处理，以尽量减少或基本消除生物体对医疗器械进入生物体后产生的反应。医疗器械可涂覆各种生物相容性材料。治疗药物、药剂或化合物可与生物相容性材料混合，并粘附在医疗设备的至少一部分上。这些治疗剂或化合物还可进一步降低生物体对医疗器械进入生物体后的反应。此外，这些治疗药物、制剂和/或化合物还可用于促进愈合，包括预防血栓形成。这些药物、制剂和/或化合物还可用于治疗特定疾病，包括易损斑块。治疗剂也可输送到疾病部位的区域。在区域性给药中，液体制剂可能是提高特定药物疗效和可给药性的理想选择。此外，还可对装置进行改良，以促进内皮化。可利用各种材料和涂层方法将药剂或化合物保持在医疗器械上，直至输送和定位。此外，还可对用于递送植入式医疗器械的装置进行改良，以降低在递送过程中损坏植入式医疗器械的可能性。医疗器械包括支架、移植物、吻合器、血管周围包裹物、缝合线和订书钉。此外，还可利用各种聚合物组合来控制治疗药物、制剂和/或化合物从植入式医疗器械中的洗脱率。
• Local vascular delivery of mTor inhibitors in combination with peroxisome proliferators-activated receptor stimulators
  申请人：Cordis Corporation

  公开号：EP2042202A2

  公开（公告）日：2009-04-01

  Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or compounds may also be utilized to treat specific disorders, including vulnerable plaque, and athereosclerosis in type 2 diabetic patients. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

  医疗器械，尤其是植入式医疗器械，可以进行涂层处理，以尽量减少或基本消除生物体对医疗器械进入生物体后的反应。医疗器械可涂覆各种生物相容性材料。治疗药物、药剂或化合物可与生物相容性材料混合，并粘附在医疗设备的至少一部分上。这些治疗剂或化合物还可进一步降低生物机体对医疗器械进入生物机体的反应。此外，这些治疗药物、制剂和/或化合物还可用于促进愈合，包括预防血栓形成。这些药物、制剂和/或化合物还可用于治疗特定疾病，包括易损斑块和 2 型糖尿病患者的动脉粥样硬化。治疗剂也可输送到疾病部位的区域。在区域给药中，液体制剂可能是提高特定药物疗效和可给药性的理想选择。此外，还可对装置进行改良，以促进内皮化。可利用各种材料和涂层方法将药剂或化合物保持在医疗器械上，直至输送和定位。此外，还可对用于递送植入式医疗器械的装置进行改良，以降低在递送过程中损坏植入式医疗器械的可能性。此外，还可利用各种聚合物组合来控制治疗药物、药剂和/或化合物从植入式医疗器械中的洗脱率。
• Device for local and/or regional delivery employing liquid formulations of therapeutic agents
  申请人：Cordis Corporation

  公开号：EP2108390A2

  公开（公告）日：2009-10-14

  Medical devices may be utilized for local and regional therapeutic agent delivery. These therapeutic agents or compounds may reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or compounds may also be utilized to treat specific disorders, including restenosis, vulnerable plaque, and atherosclerosis in type 2 diabetic patients. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Various materials and coating methodologies may be utilized to maintain the agents or compounds on the medical device until delivered and positioned.

  医疗器械可用于局部和区域治疗剂的输送。这些治疗剂或化合物可减轻生物机体对医疗器械进入机体的反应。此外，这些治疗药物、制剂和/或化合物还可用于促进愈合，包括预防血栓形成。这些药物、制剂和/或化合物还可用于治疗特定疾病，包括 2 型糖尿病患者的再狭窄、易损斑块和动脉粥样硬化。在区域给药方面，液体制剂可提高特定药物的疗效和可给药性。可利用各种材料和涂层方法将药剂或化合物保持在医疗设备上，直至输送和定位。
• DEVICE FOR LOCAL AND/OR REGIONAL DELIVERY EMPLOYING LIQUID FORMULATIONS OF THERAPEUTIC AGENTS
  申请人：Zhao Jonathon Z.

  公开号：US20080181927A1

  公开（公告）日：2008-07-31

  Medical devices may be utilized for local and regional therapeutic agent delivery. These therapeutic agents or compounds may reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or compounds may also be utilized to treat specific disorders, including restenosis, vulnerable plaque, and atherosclerosis in type 2 diabetic patients. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Various materials and coating methodologies may be utilized to maintain the agents or compounds on the medical device until delivered and positioned.